Want to see DE:AAQ1 full AI Analyst Report?
aap Implantate (AAQ1) AI Stock Analysis
aap Implantate
(XETRA:AAQ1)
The overall score of 42 is driven mainly by weak financial performance, with persistent operating and net losses, consistently negative cash flows, and gradual equity erosion despite very strong gross margins and low leverage, while secondary pressure comes from a modestly bearish technical setup and limited valuation support given negative earnings and no dividend.
aap Implantate (AAQ1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 21.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,632
- Price to Earnings (P/E)
- -7.4
- Beta (1Y)
- -0.13
- Revenue Growth
- 1.81%
- EPS Growth
- 42.09%
- Country
- Germany
- Employees
- 105
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
aap Implantate Business Overview & Revenue Model
Company Description
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international reg...
How the Company Makes Money
aap Implantate generates revenue primarily by selling orthopedic/trauma implant systems and associated surgical instrumentation to healthcare providers (such as hospitals and surgical centers), either directly or via distribution partners. Key revenu...
aap Implantate Financial Statement Overview
Summary
Revenue around €12.8 million is broadly flat over time but has recently declined, and despite structurally strong gross margins above 80% of sales, the company continues to post operating and net losses with consistently negative operating and free cash flows, leading to erosion of the equity base and indicating weak overall financial performance.
Income Statement
35NegativeBalance Sheet
60NeutralCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.78M | 12.50M | 12.20M | 11.48M | 11.52M | 12.17M |
| Gross Profit | 11.38M | 10.80M | 10.67M | 9.74M | 10.58M | 2.32M |
| EBITDA | -815.20K | -632.00K | -1.19M | -3.43M | -1.57M | -520.00K |
| Net Income | -2.73M | -2.60M | -3.63M | -5.13M | -2.56M | -2.52M |
Balance Sheet | ||||||
| Total Assets | 16.11M | 13.75M | 15.84M | 19.47M | 20.23M | 22.95M |
| Cash, Cash Equivalents and Short-Term Investments | 286.00K | 1.40M | 2.46M | 1.64M | 236.00K | 2.11M |
| Total Debt | 3.97M | 984.00K | 1.72M | 5.29M | 3.17M | 5.08M |
| Total Liabilities | 7.93M | 5.06M | 5.38M | 8.63M | 7.40M | 10.18M |
| Stockholders Equity | 8.18M | 8.70M | 10.46M | 10.85M | 12.83M | 12.78M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -2.16M | -1.45M | -3.40M | -2.38M | -2.99M |
| Operating Cash Flow | -1.33M | -1.43M | -1.12M | -2.99M | -1.89M | -2.47M |
| Investing Cash Flow | -876.00K | -670.00K | -327.00K | -397.00K | -469.00K | 155.00K |
| Financing Cash Flow | 2.27M | 859.00K | 2.22M | 4.42M | 475.00K | 3.53M |
aap Implantate Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.40 is below the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.60, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 37.36 is Neutral, neither overbought nor oversold. The STOCH value of 62.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.
aap Implantate Peers Comparison
Overall Rating
DE:AFX73Outperform
DE:EUZ69Neutral
DE:GME51Neutral- DE:AAQ142Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| DE:AFX | 73Outperform | EUR 3.13B | 20.95 | 5.52% | 1.57% | -0.06% | -38.81% |
| DE:EUZ | 69Neutral | EUR 832.23M | 16.63 | 19.49% | 1.65% | 4.42% | 35.68% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| DE:GME | 51Neutral | EUR 11.71M | -15.40 | -4.38% | 4.65% | 1.58% | -148.73% |
| DE:AAQ1 | 42Neutral | EUR 21.34M | -7.44 | -32.36% | ― | 1.81% | 42.09% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:AAQ1 | aap Implantate | 1.45 | -0.02 | -1.36% | |
| DE:AFX | Carl Zeiss Meditec | 34.98 | -6.98 | -16.63% | |
| DE:EUZ | Eckert & Ziegler Strahlen und Medizintechnik | 13.30 | -2.88 | -17.79% | |
| DE:GME | Geratherm Medical | 2.15 | -1.53 | -41.56% | |
| DE:MF6 | MagForce AG | ― | ― | ― | |
| DE:E8X | elexxion AG | 0.01 | -0.13 | -91.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 30, 2026